News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.


Posted on: 03/30/2008

Expert Opin Biol Ther. 2008 Apr;8(4):541-553. Related Articles


Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ.

1Associate Professor Duke University Medical Center, Neuro-Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA +1 919 684 5301 ; +1 919 684 6674 ; reard003@mc.duke.edu , 2Clinical Director Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, SW430, 44 Binney Street, Boston, MA 02115, USA, 3Assistant Professor Duke University Medical Center, Department of Medicine, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA, 4Associate Professor Massachusetts General Hospital, Department of Neurology, 100 Blossom Street, Boston, MA 02114, USA, 5Associate Professor Duke University Medical Center, Department of Medicine, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA.

Background: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors. Objective: To summarize the clinical experience of VEGF-directed treatment for malignant glioma. Methods: We reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. Results/conclusions: Recent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.

PMID: 18352856 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740